Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

Tomonori Hirashima, Minoru Takada, Takefumi Komiya, Takashi Nitta, Kobayashi Masashi, Noriyuki Masuda, Kaoru Matui, Masanori Kikui, Tsutomu Yasumitsu, Ichirou Kawase

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymun-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P < 0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P = 0.0040 for CYFRA 21-1, P < 0.001 for PS, P = 0.0052 for Stage).

Original languageEnglish (US)
Pages (from-to)4713-4716
Number of pages4
JournalAnticancer Research
Issue number6 B
StatePublished - 1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic significance of CYFRA 21-1 in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this